![Perry Nisen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Perry Nisen
Director/Board Member at
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Net worth: 4 M $ as of 30/06/2026
Profile
Dr. Perry D.
Nisen is a Chief Executive Officer & Director at Quanta Therapeutics, Inc. and an Independent Director at Teva Pharmaceutical Industries Ltd. He is on the Board of Directors at Quanta Therapeutics, Inc., Teva Pharmaceutical Industries Ltd. and California Biomedical Innovation Alliance.
Dr. Nisen was previously employed as an Executive Partner, Private Equity by Sofinnova Investments, Inc., an Independent Director by Mirna Therapeutics, Inc., a Chief Executive Officer & Trustee by Sanford Burnham Prebys Medical Discovery Institute, a Senior Vice President-Science & Innovation by GlaxoSmithKline LLC, a VP-Cancer Research & Oncology Development by Abbott Laboratories, and a Professor by The University of Texas Southwestern Medical Center.
He also served on the board at Xylocor Therapeutics, Inc. He received his undergraduate degree from Stanford University, a graduate degree from Albert Einstein College of Medicine, Inc. and a doctorate degree from Albert Einstein College of Medicine, Inc..
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 05/06/2026 | 1,19,807 ( 0.01% ) | 4 M $ | 30/06/2026 |
Perry Nisen active positions
| Companies | Position | Start |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Director/Board Member | 14/07/2017 |
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology Provides biomedical advocacy and community services | Director/Board Member | 23/11/2015 |
Quanta Therapeutics, Inc.
 Quanta Therapeutics, Inc. BiotechnologyHealth Technology Develops allosteric inhibitors for RAS-driven cancers | Chief Executive Officer | 01/07/2021 |
Former positions of Perry Nisen
| Companies | Position | End |
|---|---|---|
Sanford Burnham Prebys Medical Discovery Institute
 Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Conducts medical research | Chief Executive Officer | 30/09/2017 |
Mirna Therapeutics, Inc.
 Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Director/Board Member | 01/01/2017 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01/09/2014 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/2004 |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel gene therapy for cardiovascular disease | Director/Board Member | - |
Training of Perry Nisen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
95
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
Abbott Laboratories
 Abbott Laboratories Medical SpecialtiesHealth Technology Develops and manufactures medical devices, diagnostic systems, pharmaceuticals & nutritional products | Health Technology |
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Finance |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Conducts medical research | Health Services |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in the development of micro ribonucleic acid based oncology therapeutics | Commercial Services |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas Southwestern Medical Center
 The University of Texas Southwestern Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology Provides biomedical advocacy and community services | Health Technology |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel gene therapy for cardiovascular disease | Health Technology |
Quanta Therapeutics, Inc.
Quanta Therapeutics, Inc. BiotechnologyHealth Technology Develops allosteric inhibitors for RAS-driven cancers | Health Technology |
- Stock Market
- Insiders
- Perry Nisen
